Tokola O, Tenhunen R, Volin L, Mustajoki P
Br J Clin Pharmacol. 1986 Sep;22(3):331-5. doi: 10.1111/j.1365-2125.1986.tb02895.x.
The pharmacokinetics of haem were investigated after intravenous administration of a therapeutic dose of haem arginate (3 mg haem kg-1) to four healthy volunteers and four symptomless porphyric patients. Plasma haem concentrations were measured also during a treatment course of four infusions in six patients with porphyria. Plasma haem concentrations declined monoexponentially over 48 h in both healthy volunteers and porphyric patients, with a mean +/- s.e. mean elimination half-life of 10.8 +/- 0.6 h. Other kinetic parameters were also similar in the two groups, total plasma clearance was 3.7 +/- 0.4 ml min-1 and volume of distribution was 3.37 +/- 0.34 l. In the multiple dose study the elimination half-life increased significantly, from 11.3 +/- 0.4 h to 18.1 +/- 1.4 h over 4 consecutive days. Plasma haemopexin values decreased with time after a single haem arginate dose. The infusion of haem arginate did not cause thrombophlebitis.
对四名健康志愿者和四名无症状卟啉症患者静脉注射治疗剂量的精氨酸血红素(3毫克血红素/千克)后,研究了血红素的药代动力学。在六名卟啉症患者进行四次输注的治疗过程中也测量了血浆血红素浓度。在健康志愿者和卟啉症患者中,血浆血红素浓度在48小时内呈单指数下降,平均消除半衰期为10.8±0.6小时。两组的其他动力学参数也相似,总血浆清除率为3.7±0.4毫升/分钟,分布容积为3.37±0.34升。在多剂量研究中,消除半衰期显著增加,在连续4天内从11.3±0.4小时增加到18.1±1.4小时。单次注射精氨酸血红素后,血浆血红素结合蛋白值随时间下降。输注精氨酸血红素未引起血栓性静脉炎。